The purpose of this clinical trial is to characterize drug interactions between one medicinal herb widely used by HIV infected patients: Echinacea sp. and the protease inhibitor darunavir/ritonavir.
15 patients on antiretroviral therapy with darunavir/ritonavir 600/100 mg twice a day during four weeks will be recruited. The patients will receive treatment with Echinacea purpurea for 14 days, 500 mg every 6 hours. A 12 hour pharmacokinetic curve will be obtained at baseline and on day 14.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
Lluita contra la Sida Foundation, HIV Unit, Irsi Caixa Foundation
Badalona, Spain
plasma concentration of darunavir and ritonavir
Time frame: DAY 14
Clearance (CL/F)
Time frame: DAY 14
Volume of distribution (V/F)
Time frame: DAY 14
Elimination half-life (t1/2)
Time frame: DAY 14
Area under the plasma concentration-time curve during the dosing interval
Time frame: DAY 14
Adverse events and laboratory alterations
Time frame: DAY 14
HIV Viral load in plasma
Time frame: DAY 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.